Pioneering Spirit in the Modern Era
Formed in 1998, Braasch was initially focused in rotavirus DNA vaccines, delivery systems and multiple subunit vaccines, however due to early success with anti-somatostatin vaccine platform technology, in 2008 Braasch made the strategic decision to focus on a singular purpose; developing and licensing the world's first highly effective somatostatin-based (GH and IGF-1) vaccines.

Using 29 years of experience in vaccine development, along with a track record of more than 65 successful US and International vaccine registrations, Dr Keith Haffer, the principal behind Braasch Biotech, believed that first-generation somatostatin vaccine technology could be enhanced and optimized to create a valuable new proprietary second-generation somatostatin vaccine technology with a superior efficacy and safety profile.

In addition to successfully creating and testing its new second-generation somatostatin vaccine technology, the company has also expanded its exclusive intellectual property positions including four separate US and PCT filings and anticipate several additions filings to support our novel technology.